DC-NANOCHON
6.5.2024 17:01:26 CEST | Business Wire | Press release
Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round.
The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others.
Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team.
“We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care.”
Nanochon will initiate a phase I trial in the US this year for its patented knee implant Chondrograft™. The device requires only minimally invasive surgery to regrow damaged cartilage and bone to stave off the need for full knee replacements which are costly and have a long recovery time.
Holmes follows, “We’ve had fantastic success in our animal studies and we’re very optimistic about future implications in human knees and other joints.”
Nanochon is a biotech and medical device company focused on developing innovative orthopedic solutions. Chondrograft™ is a minimally-invasive implant that allows for immediate weight-bearing and motion – meaning less time spent recovering. Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care. Our mission is to develop a new approach to treat cartilage replacement and repair so that the hundreds of thousands of young, active patients with joint damage can return to their lifestyles without having to undergo costly and invasive short-term fixes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503575444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Opens Expanded Histotripsy Training Center in Hong Kong20.7.2026 14:00:00 CEST | Press release
HistoSonics today announced the opening of its expanded Histotripsy Training Center in Hong Kong, reinforcing the city's position as a leading hub for physician education, clinical collaboration, and innovation in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720812810/en/ Pictured at the expanded Histotripsy Training Center in Hong Kong. Front row (left to right): Dr. Angus Yuen, Chief Medical Officer, Gleneagles Hospital Hong Kong; Prof. Albert Chan, Director of Liver Cancer Surgery Centre, Gleneagles Hospital Hong Kong; Dr. Kenneth Tsang, Regional Chief Executive Officer, IHH Healthcare North Asia, and Chief Executive Officer, Gleneagles Hospital Hong Kong; Dr. Vince Lau, Director of Interventional Radiology Centre, Gleneagles Hospital Hong Kong; Dr. Joe Herman, Vice President, Medical Affairs, HistoSonics. Back row (left to right): Jay Lee, APAC Regional Manager, HistoSonics; Eric Kwong, Hong Kong Sales Manager
Shaping a Generation Through Dialogue: Inside the Doha Debates Ambassador Program20.7.2026 13:29:00 CEST | Press release
Applications are open for young people from around the world to learn to engage and lead through truth-seeking conversations about complex global issues In a world shaped by change and competing narratives, the ability to listen, question and engage in constructive dialogue has never been more critical. Through the Doha Debates Ambassador Program, a production of Qatar Foundation, young people from around the world are not only learning these skills, but actively applying them in their communities, careers and areas of study. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260720452437/en/ Shaping a Generation Through Dialogue: Inside the Doha Debates Ambassador Program. Applications are open for young people from around the world to learn to engage and lead through truth-seeking conversations about complex global issues. (Photo: AETOSWire) This online educational program teaches young people from across the globe to debate d
Kinaxis Appoints Herb Yeh as Chief Financial Officer and Chief Strategy Officer20.7.2026 13:01:00 CEST | Press release
Seasoned corporate finance veteran brings more than 25 years of experience working with enterprise software companies through growth, M&A, and strategic transformation Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today announced the appointment of Herb Yeh as Chief Financial Officer and Chief Strategy Officer, effective July 27, 2026. In this role, Yeh will oversee the global finance organization and corporate strategy operations at Kinaxis, leading all Finance, Accounting, Investor Relations, Corporate Strategy, and Corporate Development. He will work closely with the executive leadership team and Board of Directors to support disciplined execution, long-term growth, and shareholder value creation. "Herb has spent his career working with boards and management teams at their most critical inflection points in enterprise software, and we are thrilled to have him join Kinaxis," said Razat Gaurav, Chief Executive Officer of Kinaxis. "He has followed
IFF Announces Agreement to Sell Its Portfolio of Botanical Extracts, Vitamins & Minerals and Food Enhancement Activities to SuanNutra, a Portfolio Company of Carbyne Equity Partners.20.7.2026 12:45:00 CEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, and health and biosciences — today announced that it has entered into an agreement with SuanNutra, a Carbyne Equity Partners portfolio company and global provider of science-backed branded and functional ingredients, to sell its portfolio of botanical extracts, vitamins and minerals, and food enhancement activities, including its range of natural colors and antioxidants and certain localized flavor activities in Peru. The portfolio serves a broad range of food, beverage and nutritional end markets through a comprehensive selection of customized solutions. “These businesses are highly respected, and we are confident they will continue to thrive under the ownership of SuanNutra and Carbyne,” said Erik Fyrwald, CEO IFF. “This transaction is another step in optimizing our portfolio and reinforces our focus on our core innovation-led businesses — Taste, Scent and Health & Biosciences — where we see the greatest opportunities to drive
NIQ Appoints Irina Stoian as Chief AI Commercial Officer20.7.2026 12:45:00 CEST | Press release
New executive role strengthens NIQ’s AI strategy and advances the company’s position as a trusted intelligence infrastructure powering AI-driven commerce NIQ today announced that Irina Stoian has joined the company as Chief AI Commercial Officer, a newly created role designed to accelerate NIQ’s enterprise AI commercial strategy and help clients turn the company’s AI capabilities into business impact and growth. Stoian will help align Product, Technology, Commercial, Partnerships, and Marketing around a unified AI growth strategy. Her remit includes shaping commercial AI offerings, strategic partnerships, pricing and business models, and deeper integration of NIQ capabilities into client workflows. The appointment builds on NIQ’s broader AI strategy, which positions the company as a trusted intelligence infrastructure powering AI-driven commerce. Across its AI portfolio, including ConnectAI, NIQ Optiq™, and NIQ Cadence™, NIQ is expanding how clients access trusted data, intelligence, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom